Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114777 · ClinicalTrials.gov registry record · Phase 3
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 595
- Enrollment target
NCT00114777 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 595 participants.
The verdict
NCT00114777, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 595 participants
- Enrollment target
Study Summary
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.
Interventions
- DRUG Cyclosporin A
- DRUG Belatacept Less Intensive Regimen (LI)
- DRUG Belatacept More Intensive Regimen (MI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2005-02 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114777
The ClinicalTrials.gov registry entry for NCT00114777 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclosporin A is the first listed.
NCT00114777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114777 about?
NCT00114777 is a clinical study titled "Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant". The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.
What is the current status of trial NCT00114777?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 595 participants. The study started on 2005-02. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00114777?
The interventions under investigation include: Cyclosporin A (DRUG), Belatacept Less Intensive Regimen (LI) (DRUG), Belatacept More Intensive Regimen (MI) (DRUG).
Who is sponsoring clinical trial NCT00114777?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.